Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Immunomodulation of the Prostate Tumor Microenvironment Following Inorganic Arsenic Exposure.

Shearer JJ., Rivera-Cruz C., Cavalca AMB., Fonseca-Alves CE., Figueiredo ML.

Animal Study on Immune Modulation, published in J Appl Toxicol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Appl Toxicol (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41730271
DOI
10.1002/jat.70108

Abstract (original English)

The tumor microenvironment (TME) influences prostate cancer (PCa) progression through stromal and immune interactions. Adipose-derived mesenchymal stromal cells (ASCs) modulate immune tone, while inorganic arsenic (iAs), a widespread toxicant, is linked to immune suppression and carcinogenesis. Their combined impact on PCa immunity has remained unclear. Using a Ras-driven murine PCa model (TC2Ras, which mimics aggressive, immune-interactive PCa through constitutive Ras signaling), we assessed ASC and chronic iAs exposure effects on tumor growth, immune infiltration, and transcriptomic remodeling via flow cytometry, RNA-seq, and qPCR. ASC-conditioned media increased TC2Ras viability by up to 82%, an effect reversed by iAs (300-1000 ppb). In vivo, ASC co-implantation significantly elevated tumor weight in ASC + iAs tumors. ASC promoted approximately twofold macrophage and CD4 + T-cell infiltration, while iAs suppressed macrophages and MDSCs. We performed RNA-seq and qPCR, confirming that a sustained IFNγ-IRF1 activation (approximately eightfold) in ASC tumors occurred alongside an iAs-driven downregulation of adaptive immunity, as well as an upregulation of immune checkpoint genes (Pdcd1, Lag3). These findings demonstrate that ASC-iAs crosstalk remodels the TME toward immune tolerance and chronic IFNγ signaling, potentially facilitating tumor progression and revealing novel mecha

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MaleAnimalsTumor MicroenvironmentProstatic NeoplasmsArsenicImmunomodulationMiceMesenchymal Stem CellsInterferon-gammaMice, Inbred C57BL

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research